Vor Biopharma
About: Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
Employees: 168
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
500% more call options, than puts
Call options by funds: $78K | Put options by funds: $13K
102% more capital invested
Capital invested by funds: $33.5M [Q3] → $67.6M (+$34.1M) [Q4]
18.8% more ownership
Funds ownership: 69.93% [Q3] → 88.73% (+18.8%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
6% less funds holding
Funds holding: 54 [Q3] → 51 (-3) [Q4]
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
53% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 15
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Oppenheimer Matthew Biegler 7% 1-year accuracy 2 / 27 met price target | 1,040%upside $8 | Outperform Reiterated | 21 Mar 2025 |
Stifel Stephen Willey 25% 1-year accuracy 5 / 20 met price target | 612%upside $5 | Buy Maintained | 21 Mar 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 21% 1-year accuracy 40 / 192 met price target | 1,752%upside $13 | Buy Maintained | 21 Mar 2025 |
Financial journalist opinion









